Key clinical point: Ustekinumab and a tumor necrosis factor inhibitor (TNFi) showed comparable efficacy, safety, and drug persistence after 1 year of treatment i n real-world patients with psoriatic arthritis (PsA).
Major finding: After 1 year of treatment, ustekinumab vs. TNFi showed similar persistence (hazard ratio for stopping/switching treatment 0.82; 95% CI 0.60-1.13) and a similar proportion of patients achieving clinical low disease activity on the Disease Activity Index for PsA (odds ratio [OR] 0.80; 95% CI 0.57-1.10) and remission (OR 0.73; 95% CI 0.49-1.07), along with a similar safety profile.
Study details: Findings are from a 1-year analysis of the prospective, observational PsABio study including 893 patients with PsA who were prescribed first-line to third-line ustekinumab or TNFis.
Disclosures: PsABio study was sponsored by Janssen. The authors declared receiving grants, personal fees, consulting fees, research support, nonfinancial support, and honoraria from several sources, including Janssen. Three authors declared being employees or shareholders of Janssen or Johnson and Johnson, Janssen’s corporate parent.
Source: Gossec L et al. Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study. Ann Rheum Dis. 2022 (Feb 24). Doi: 10.1136/annrheumdis-2021-221640